— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year. Analysts estimated a loss of $0.25 per share
— Net sales dropped to $59 thousand from $372 thousand in the same period of last year, vs. $190 thousand expected
— Net loss before recognition of the deemed dividends was $5.3 million
— Operating expenses were $5.2 million in Q3, compared with $10.3 million in the third quarter of 2018
— Completed interaction with the FDA, related to the chemistry and manufacturing package required to support the NDA for Neutrolin
— In September, closed an exchange agreement with funds managed by Elliott Management Corporation, CorMedix’s largest investor
Most Popular
DG Earnings: All you need to know about Dollar General’s Q4 2024 earnings results
Dollar General Corporation (NYSE: DG) reported its fourth quarter 2024 earnings results today. Net sales increased 4.5% year-over-year to $10.3 billion. Same-store sales increased 1.2%. Net income of $191.2 million was
Adobe (ADBE) reports higher Q1 revenue, adjusted earnings
Adobe Inc. (NASDAQ: ADBE) on Wednesday reported an increase in revenue and adjusted profit for the first quarter of 2025. The numbers also exceeded Wall Street's expectations. The design software
Darden Restaurants likely to report higher sales and profit for Q3 2025
Despite rising costs and shifting consumer habits, Darden Restaurants, Inc. (NYSE: DRI) has maintained stable performance, reflecting the unwavering popularity of its brands and their ability to compete effectively in
